Winton Group LTD Exelixis, Inc. Transaction History

Winton Group LTD

$1.5 Billion
Q1 2025

A detailed history of Winton Group LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Winton Group LTD holds 197,441 shares of EXEL stock, worth $8.37 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares

197,441

Previous 39,536 399.4%

Holding current value

$8.37 Million

Previous $1.32 Million 453.88%

% of portfolio

0.49%

Previous 0.1%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$32.38 - $39.16 $5.11 Million - $6.18 Million	157,905 Added 399.4%	197,441 $7.29 Million
Q4 2024 Feb 12, 2025	SELL	$25.39 - $36.46 $5.82 Million - $8.36 Million	-229,317 Reduced 85.29%	39,536 $1.32 Million
Q3 2024 Nov 12, 2024	BUY	$21.96 - $27.6 $4.92 Million - $6.19 Million	224,269 Added 503.03%	268,853 $6.98 Million
Q2 2024 Aug 09, 2024	BUY	$20.34 - $23.73 $1,545 - $1,803	76 Added 0.17%	44,584 $1 Million
Q1 2024 May 14, 2024	BUY	$20.17 - $23.93 $448,177 - $531,724	22,220 Added 99.69%	44,508 $1.06 Million
Q4 2023 Feb 12, 2024	SELL	$19.25 - $24.13 $14,341 - $17,976	-745 Reduced 3.23%	22,288 $534,000
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $32,348 - $38,635	-1,699 Reduced 6.87%	23,033 $503,000
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $3.5 Million - $3.94 Million	-192,453 Reduced 88.61%	24,732 $472,000
Q1 2023 May 12, 2023	BUY	$16.3 - $19.41 $559,905 - $666,733	34,350 Added 18.79%	217,185 $4.22 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $546,653 - $635,447	36,541 Added 24.98%	182,835 $2.93 Million
Q3 2022 Nov 10, 2022	BUY	$15.68 - $22.27 $82,367 - $116,984	5,253 Added 3.72%	146,294 $2.29 Million
Q2 2022 Aug 10, 2022	BUY	$17.44 - $23.16 $1.3 Million - $1.73 Million	74,720 Added 112.66%	141,041 $2.94 Million
Q1 2022 May 11, 2022	BUY	$17.03 - $22.67 $43,971 - $58,533	2,582 Added 4.05%	66,321 $1.5 Million
Q4 2021 Feb 10, 2022	BUY	$15.84 - $21.88 $160,886 - $222,235	10,157 Added 18.96%	63,739 $1.17 Million
Q3 2021 Oct 28, 2021	BUY	$16.3 - $21.14 $6,161 - $7,990	378 Added 0.71%	53,582 $1.13 Million
Q2 2021 Aug 10, 2021	SELL	$17.95 - $25.56 $99,532 - $141,730	-5,545 Reduced 9.44%	53,204 $969,000
Q1 2021 Jul 21, 2021	SELL	$20.53 - $25.22 $310,618 - $381,578	-15,130 Reduced 20.48%	58,749 $1.33 Million
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $2.95 Million - $3.98 Million	-160,336 Reduced 68.46%	73,879 $1.48 Million
Q3 2020 Oct 30, 2020	BUY	$20.67 - $26.94 $234,852 - $306,092	11,362 Added 5.1%	234,215 $5.73 Million
Q2 2020 Aug 05, 2020	SELL	$16.46 - $27.42 $4.29 Million - $7.14 Million	-260,568 Reduced 53.9%	222,853 $5.29 Million
Q1 2020 May 11, 2020	SELL	$14.46 - $21.8 $3.04 Million - $4.58 Million	-209,990 Reduced 30.28%	483,421 $8.33 Million
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $9.47 Million - $11.8 Million	625,051 Added 914.35%	693,411 $12.2 Million
Q3 2019 Nov 08, 2019	BUY	$17.68 - $22.65 $726,329 - $930,507	41,082 Added 150.6%	68,360 $1.21 Million
Q2 2019 Jul 08, 2019	BUY	$18.93 - $24.75 $309,675 - $404,885	16,359 Added 149.82%	27,278 $583,000
Q1 2019 May 13, 2019	BUY	$19.6 - $24.76 $214,012 - $270,354	10,919 New	10,919 $260,000
Q4 2018 Feb 05, 2019	SELL	$13.65 - $21.8 $186,813 - $298,354	-13,686 Closed	0 $0
Q3 2018 Nov 02, 2018	SELL	$15.87 - $22.4 $173,141 - $244,383	-10,910 Reduced 44.36%	13,686 $0
Q2 2018 Aug 20, 2018	SELL	$18.56 - $22.45 $397,889 - $481,283	-21,438 Reduced 46.57%	24,596 $0
Q1 2018 May 21, 2018	BUY	$22.15 - $31.89 $1.02 Million - $1.47 Million	46,034 New	46,034 $0

Others Institutions Holding EXEL

# of Institutions

613

Shares Held

257M

Call Options Held

1.57M

Put Options Held

730K

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $13.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.

Account